-
-
The good news is that HIV advocacy groups, clinicians, and others haven't seen so many HIV/AIDS program federal budget increases since the 1990s. The bad news is that it might be too little, too late in a recessionary environment in which state budgets are forcing draconian cuts.
-
An open-label, randomized, controlled trial of early vs. delayed initiation of HAART was conducted in 642 patients with active TB and HIV infection in Durban, South Africa.
-
On April 27, 2010, FDA approved a new dosing regimen for lopinavir/ritonavir (Kaletra®) tablets and oral solution.
-
The current economy should be enough to convince clinical research (CR) sites that they need better strategies to handle the rollercoaster ride of the research business cycle if they want to survive and thrive for the long term.
-
Assessing a protocol's feasibility should be a top priority for clinical trial sites. And it's a good strategy to have a thorough feasibility process in place.
-
Clinical trials directors should take reasonable steps to manage their organization's risk in human subjects research. It's not wise to assume that someone else is taking care of this issue, an expert advises.
-
It's good timing to improve your research compliance program now that billions more dollars in federal funding from the health care reform and stimulus package continue to be pumped into the research economy. Such money brings increased regulatory scrutiny, and this means clinical trial (CT) sites will need to make certain they are following all rules.
-
Cancer Care Northwest of Spokane, WI, is proof that a clinical research site doesn't need to be large to have a successful billing compliance program.
-
It's the rare clinical trial site that stays consistently busy with research. Most sites need to do at least a little marketing. Only they might not call it that, or even have a business strategy for recruiting and maintaining a steady business stream.
